Trabeculectomy surgery is one of the most common procedures performed in the management of patients with glaucoma since its introduction 40 years ago. 1 More recently, the adjunctive use of antimetabolite agents such as mitomycin C (MMC) and 5-fluorouracil has been introduced to enhance surgical success. 2e5 These agents inhibit fibroblastic proliferation in wound healing, thus preventing excessive scar tissue formation at the level of the subconjunctival plane, which may otherwise compromise aqueous flow and lead to surgical failure. However, the use of antimetabolites may result in more postoperative complications 2 6 7 including serious sight-threatening complications such as endophthalmitis, overfiltration and hypotonous maculopathy. 8 The Ologen collagen matrix implant (ProTop & MediKing, Taipei, Taiwan) is a disc-shaped porcinederived biodegradable collagen matrix that has been developed to prevent excessive scarring after trabeculectomy. It is composed of a three-dimensional porous structure of collageneglycosaminoglycan copolymers. During trabeculectomy surgery, the implant is placed on top of the sclera flap before the conjunctiva is closed over it. The implant aims to regulate aqueous flow by keeping pressure on top of the sclera flap and by acting as a reservoir as aqueous humour gets absorbed into its porous structure. 9 10 The collagen matrix attempts to provide a scaffold for growth of fibroblasts and guides the fibroblasts to grow through the matrix pores in a random and diffuse fashion rather than in an organised way, thus altering tissue remodelling in the trabeculectomy wound and reducing scar formation. The eventual result after resorption of the matrix would be a loosely structured filtering bleb. 9 10 Bleb morphologic features are an important clinical indicator of bleb function and can be used to predict longer-term success and bleb-related complications. 11 12 Many clinical bleb grading systems are currently in use, 11 13 14 such as the Moorfields bleb grading system (MBGS), 14 which assesses various parameters of bleb morphologic features such as bleb area, height and vascularity. Anterior segment optical coherence tomography (ASOCT) has been used to image trabeculectomy blebs 15e17 and was found to demonstrate bleb morphologic features that were otherwise not apparent on clinical examination at the slit lamp. Clinical bleb grading has also been reported to show good correlation with ASOCT bleb grading. 18 Previous studies have also used ASOCT to image Ologen implants after trabeculectomy surgery in rabbits, 9 10 but to date, no such study has been described in human beings, although a recent study by Aptel et al described the use of ASOCT to image Ologen implants used in deep sclerectomy. 19 Our study describes the use of ASOCT to image filtering blebs of phacotrabeculectomies performed with Ologen implant, and we compared these with blebs associated with phacotrabeculectomies modulated by MMC. We also examined the degradation of these implants over time using ASOCT.
METHODS

Study population
This was a prospective interventional caseecontrol study. Informed consent was obtained from all patients, and the study was conducted in accordance with the principles of the Declaration of Helsinki and had the approval of the ethics committee of the Singapore Eye Research Institute.
The study population included individuals aged $21 years, with primary glaucoma (primary angle-closure glaucoma (PACG) and primary open-angle glaucoma (POAG)) with uncontrolled intraocular pressure (IOP) and failed medical and laser treatments, and visually significant cataract. The exclusion criteria included individuals with known allergy to porcine collagen or religious background contraindicating its use, vertical cup-to-disc ratio $0.9, diagnosis of secondary glaucoma, previous intraocular surgery, ocular infection 14 days before surgery, warfarin use that could not be discontinued or individuals who were pregnant or breastfeeding.
Intervention and surgical technique
The experimental group included 33 participants (17 with PACG and 16 with POAG), who underwent phacotrabeculectomy with an Ologen implant (model No 83068; diameter 7 mm; height 4 mm). Phacotrabeculectomy was performed using standard techniques, using a two-site approach. In brief, phacoemulsification was performed through a temporal clear corneal incision and an intraocular lens was implanted in the capsular bag. A fornix-based trabeculectomy was then performed. The scleral flap was sutured with one fixed suture and one releasable suture, after which the Ologen implant was positioned on top of the scleral flap and the Tenon layer and conjunctiva were then closed over the implant (figure 1). A releasable suture was used because there was concern that it would be difficult to perform laser suture lysis over the Ologen implant. No antimetabolites were used.
The control group consisted of 33 age-and sex-matched participants (16 with PACG and 17 with POAG) who underwent combined phacotrabeculectomy surgery augmented with MMC. These were patients who were offered but refused surgery with an Ologen implant. Similar surgical methods were used with the following differences: after creation of the sclera flap but before creating the sclerostomy, three polyvinyl alcohol sponges (each approximately 533 mm) soaked in MMC (0.4 mg/ml) were applied over a wide area for 2 min. The sponges were then removed and copious irrigation with saline solution was performed. All the participants received a standardised regimen of postoperative topical antibiotics and steroids.
Clinical examination
The patients were followed-up at postoperative days 1, 7, 14, 21, 30, 60 and 90. The ophthalmologic examination included visual acuity testing, IOP measurement by Goldmann applanation tonometry and slit lamp biomicroscopic examination at each visit.
Bleb imaging by ASOCT
Bleb imaging by ASOCT (Visante; Carl Zeiss Meditec, Dublin, California, USA) was done in down gaze so as to obtain maximal cross-sectional exposure. Using a line scan oriented perpendicular to the conjunctival limbus, an ASOCT optical section (anterior segment single mode) was obtained that passed through the point of highest elevation on the surface of the bleb and the conjunctival limbus. This point was indicated by the position of a light reflex on the highest point of the bleb. For cases in which this light reflex was poorly seen, the observer manually assessed the bleb across its lateral extent using ASOCT to select an optical section that included the most elevated portion of the bleb. Generally, it was possible to obtain cross sections where the sclerostomy, sclera flap, intrascleral pathway and bleb wall were visible. Figure 2 shows an ASOCT image of a phacotrabeculectomy bleb with the Ologen implant. The bleb was demarcated as follows: a vertical line was drawn through a point at the limbus; and another vertical line, through a point 7 mm posterior to the limbus, whereas a horizontal line through these two points was used as a base; the bleb area and height within this section of the bleb was analysed. The presence of the Ologen implant was visualised by examining the cross-sectional space between the conjunctival flap and the scleral surface. The implant was seen as a structure with the same signal intensity as the surrounding conjunctiva and sclera, but which was clearly demarcated by a line of lower signal intensity, representing a potential space between the implant and the surrounding tissues. Images obtained on days 1, 30, 60 and 90 were analysed using a customised software for measuring bleb height and area 15 16 by one observer (PYB), masked to clinical and ASOCT findings.
Bleb photography
Slit lamp colour photographs of blebs were captured in diffuse illumination mode on days 1, 30 and 60. Images were captured in down gaze so as to obtain maximal exposure. These photographs were then assessed and scored according to MBGS by one observer (AN), masked to clinical and ASOCT findings, by comparing with standard reference photos.
14 The parameters assessed included bleb area, height and vascularity.
RESULTS
Baseline demographic data were comparable in both groups ( Figure 3 shows the changes in bleb morphologic features in the group with phacotrabeculectomy with MMC at days 1, 30, 60 and 90. Figure 4 shows the corresponding changes in the group with Ologen implant. The observed bleb height in the MMC group was mainly attributed to a clear aqueous lake, whereas the bleb height in the Ologen group was largely due to the mass bulk of the implant. At 90 days, the Ologen implants were graded to be still visible in 13 (39.4%) of 33 participants on ASOCT bleb scans, but these were not visible on the slit lamp.
Clinical science
Clinical bleb grading (after the MBGS) was used to score blebs for area, height and vascularity ( 
DISCUSSION
In this caseecontrol study, we found interesting differences in the blebs of eyes that underwent phacotrabeculectomy augmented with Ologen collagen matrix implants compared with those augmented with MMC over the first 3 months after surgery. Whereas there were no differences in bleb height and area over the initial 2 months, we found lower bleb height in Ologen eyes compared with MMC eyes on ASOCTat the 90-day postoperative visit. This difference in bleb height was in fact apparent in clinical bleb photographs at the 2-month visit. Bleb vascularity (on bleb photographs) was also greater, and reduction in IOP was lower in Ologen eyes at 90 days. These differences probably illustrate better overall bleb function in the MMC blebs compared with Ologen blebs, at least in the short term in the first 2e3 months after surgery. East Asian eyes have been reported to have an aggressive scarring profile after trabeculectomy surgery. 20 The Ologen implant is a possible alternative to antimetabolite use in trabeculectomy surgery because of its modulatory effect on wound healing. When implanted between the conjunctival and sclera flap, the threedimensional structure of the porous collagen polymers in the implant aim to allow random proliferation of fibroblasts through the collagen matrix, hence decreasing collagen deposition and scarring. 9 10 The Ologen implant is described to be biodegradable, and literature suggests that its degradation time is about 30e60 days. 10 However, using ASOCT, we found the implant residue to be still present in 39.4% of our patients at 90 days. Although the relevance of this is not clear at this point in time, the presence of implant residue may be reflective of varied responses in wound modulation in different eyes after surgery. Alternatively, it could represent a variation in quality control of biodegradable properties of the implant.
Comparing the ASOCT images between both groups, the bleb height in the MMC group appears to be primarily due to a clear aqueous lake (figure 3), which may represent aqueous flow, whereas the bleb height in the Ologen group seems to be largely due to the mass of the sponge (figure 4). Although a clear aqueous lake was not evident in the Ologen blebs as opposed to the MMC blebs, it is likely that pockets of aqueous exist, particularly within the body of the implant. Because the Ologen implant is a three-dimensional porous structure, it may possibly behave as a reservoir for the surrounding aqueous by acting as a physical scaffold.
In bleb height, there was a significantly lower mean bleb height in the Ologen eyes compared with the MMC eyes at 90 days. When matched for IOP (IOP #12, 13e17, and $18 mm Hg), this trend was consistent in all subgroups, although the difference did not reach statistical significance.
Coupled with the fact that IOP reduction was less in the Ologen eyes at 90 days, it is likely that the lower bleb height in these eyes could be a result of increased scarring and flattening of the Ologen blebs, compared with those in the MMC blebs. This suggests that despite the proposed effect of reducing scarring after trabeculectomy, the Ologen implant may not be as effective in reducing postoperative fibrosis compared with MMC.
Bleb morphologic features are an important clinical parameter in the assessment of bleb function. 21 Many clinical bleb grading systems are in use, including the MBGS, 14 but the major drawback of such bleb scoring systems is the subjectivity that is involved in the assessment. The use of ASOCT in bleb imaging and analysis provides a more objective platform for bleb grading and has been reported by Singh et al 15 to have good agreement with clinical bleb grading. We found that ASOCT imaging was quite consistent with clinical grading of blebs in bleb area and height. A limiting factor in bleb area analysis is the ability of the software to analyse only a proportion of the bleb and not the area in its entirety. Interestingly, the bleb vascularity score by MBGS was higher in the Ologen group, suggesting that Ologen modulation possibly has less impact on the vascular response compared with MMC.
Our study had several limitations. This was not a randomised controlled trial but a caseecontrol study. The sample size was small; hence, statistical values may have to be interpreted with caution. The ASOCT also has some limitations such as the inability to assess clinical features such as bleb vascularity and true bleb area. The study did not evaluate parameters such as bleb wall thickness, nature of cystic spaces and patency of sclera fistula, all of which may influence bleb function and clinical outcome. 22 23 Most of these observations are short term in nature, and it would be inappropriate to link these findings of bleb morphologic features to eventual surgical success. This study was a comparison of blebs in the first 3 months after surgery; the final analysis of the trial such as IOP and surgical outcome in the two groups will only be evaluated after 12 months of follow-up. Although masked to clinical data, it may have been possible for the grader to make out the presence of the Ologen implant in bleb photographs and ASOCT images, which could lead to bias in the MBGS and ASOCT assessments.
In summary, we found that 3 months after phacotrabeculectomy surgery, blebs in eyes with Ologen implants were lower in height and more vascular compared with eyes 
